Form 4: Akero Therapeutics Director Sells Shares in Novo Nordisk Merger

Akero Therapeutics Director Graham G. Walmsley disposed of common stock, restricted stock units, and stock options following the company's merger with Novo Nordisk A/S, receiving cash and contingent value rights.

Summary

• Graham G. Walmsley, a Director of Akero Therapeutics, Inc. (AKRO), reported the disposal of his beneficial ownership in the company's securities.
• The disposal occurred on December 9, 2025, as a result of the merger of Akero Therapeutics with NN Invest Sub, Inc., a subsidiary of Novo Nordisk A/S.
• At the effective time of the merger, each share of Akero Therapeutics common stock was converted into the right to receive $54.00 in cash (Closing Consideration) and one contractual contingent value right (CVR) representing the right to receive an additional $6.00 in cash if a specified milestone is achieved.
• Walmsley disposed of 93,000 shares of common stock held directly and 1,200,000 shares held indirectly through Logos Global Master Fund LP and Logos Opportunities Fund IV LP.
• Additionally, 9,398 restricted stock units (RSUs) held by Walmsley were deemed fully vested and converted into the Merger Consideration.
• 15,000 stock options with an exercise price of $50.83 were also deemed fully vested and converted into a cash payment equal to the product of the excess of the Closing Consideration ($54.00) over the exercise price, multiplied by the number of shares, plus one CVR per option.

Sentiment

Score: 7

Explanation: The filing reports the successful completion of a merger, which is a positive outcome for shareholders who receive a defined cash payment and a potential upside via a CVR. While the company ceases to exist independently, the transaction itself is a positive liquidity event for the reporting person and other shareholders.

Positives

• The completion of the merger provides a clear liquidity event for shareholders, including the reporting person, at a defined cash value.
• The inclusion of a Contingent Value Right (CVR) offers shareholders potential additional upside of $6.00 per share if a specified milestone is achieved.

Negatives

• The reporting person's direct and indirect beneficial ownership of Akero Therapeutics common stock is now zero, indicating a full exit from the company's equity.
• Akero Therapeutics, Inc. ceases to be an independent publicly traded entity, becoming a wholly-owned subsidiary of Novo Nordisk A/S.

Risks

• The $6.00 CVR payment is contingent upon the achievement of a specified milestone, meaning its receipt is not guaranteed and depends on future events.

Future Outlook

The filing primarily reports the completion of a past corporate event (merger). The only forward-looking aspect is the potential for a $6.00 CVR payment, which is contingent upon the achievement of a specified future milestone.

Industry Context

This merger signifies a strategic acquisition by Novo Nordisk A/S, a major pharmaceutical company, of Akero Therapeutics, a biopharmaceutical company. Such transactions are common in the industry as larger players seek to expand their pipelines and capabilities, particularly in promising therapeutic areas like metabolic diseases or NASH, where Akero's lead candidate, efruxifermin (EFX), is being developed. The acquisition allows Novo Nordisk to integrate Akero's assets and expertise, potentially accelerating development and commercialization with greater resources.

Comparison to Industry Standards

• The merger consideration of $54.00 cash plus a $6.00 CVR per share for Akero Therapeutics (AKRO) is consistent with premiums often observed in biopharma acquisitions, especially for companies with late-stage clinical assets.
• The use of a Contingent Value Right (CVR) is a standard mechanism in biopharmaceutical mergers to share risk and reward, linking a portion of the acquisition price to future clinical, regulatory, or commercial milestones. This structure has been seen in various industry deals, allowing acquirers to mitigate risk while providing target shareholders with potential upside.

Corporate Governance

Related Party Transactions

• The reporting person, Graham G. Walmsley, is a managing member of Logos GP LLC and Logos Opportunities IV GP LLC, which are general partners of Logos Global Master Fund LP and Logos Opportunities Fund IV LP, respectively. These funds indirectly held 1,200,000 shares of Akero Therapeutics common stock that were disposed of in the merger, representing a related party interest.

Stakeholder Impact

• Shareholders: Received $54.00 cash per share and one CVR for a potential additional $6.00, providing a clear exit and liquidity.
• Employees: Akero Therapeutics is now a wholly-owned subsidiary of Novo Nordisk, which could lead to integration and potential changes in employment structure.
• Customers/Patients: The merger could accelerate or alter the development and commercialization path of Akero's drug candidates under Novo Nordisk's larger resources.

Next Steps

• Achievement of the specified milestone for the $6.00 CVR payment.

Key Dates

Keywords

Akero Therapeutics, AKRO, Novo Nordisk, Merger, Form 4, Insider Trading, Beneficial Ownership, Contingent Value Right, CVR, Stock Disposal, Restricted Stock Units, Stock Options, Biopharma Acquisition